Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Trichrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Trichrome. Displaying page 1 of 1.
    EudraCT Number: 2008-004347-10 Sponsor Protocol Number: 20080009 Start Date*: 2009-06-17
    Sponsor Name:Amgen Inc
    Full Title: A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated with Im...
    Medical condition: Thrombocytopenia associated with ITP
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) DE (Completed) PL (Completed) BE (Completed) ES (Completed) HU (Completed) SE (Completed) EE (Completed) IT (Completed) LT (Completed) SI (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-000175-17 Sponsor Protocol Number: 1100.1448 Start Date*: 2005-05-31
    Sponsor Name: [...]
    1.
    2. Boehringer Ingelheim España, S.A.
    Full Title: A pharmacokinetic study to assess Nevirapine levels in HIV-infected patients with impaired hepatic function.
    Medical condition: Treatment of HIV infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000361-32 Sponsor Protocol Number: INCB18424-214 Start Date*: 2021-07-21
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo (TRuE-V MOA)
    Medical condition: Vitiligo
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10047642 Vitiligo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002066-24 Sponsor Protocol Number: PrE0204 Start Date*: 2015-08-28
    Sponsor Name:The All Ireland Cooperative Oncology Research Group (ICORG)
    Full Title: A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Advanced or Metastatic Cholangiocarcinoma
    Medical condition: Advanced or metastatic cholangiocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002704-34 Sponsor Protocol Number: HGS1008-C1067 Start Date*: 2007-04-27
    Sponsor Name:Human Genome Sciences, Inc.
    Full Title: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P...
    Medical condition: Chronic Hepatitis C (CHC) genotype 2/3.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10008912 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) SE (Completed) GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002703-13 Sponsor Protocol Number: HGS1008-C1060 Start Date*: 2007-03-20
    Sponsor Name:Human Genome Sciences, Inc.
    Full Title: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P...
    Medical condition: Chronic hepatitis C (CHC) genotype 1.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10008912 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) AT (Completed) FR (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005508-42 Sponsor Protocol Number: P05216 Start Date*: 2008-08-27
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    9.1 10019744 Hepatitis C PT
    9.1 10021881 Infections and infestations SOC
    9.1 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Prematurely Ended) ES (Completed) NL (Completed) IT (Completed) BE (Completed) DE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005019-96 Sponsor Protocol Number: 20101221 Start Date*: 2014-09-11
    Sponsor Name:Amgen Inc
    Full Title: A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)
    Medical condition: Immune Thrombocytopenia (ITP) in Paediatric Subjects
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10043558 Thrombocytopenia purpura LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) GB (Completed) HU (Completed) Outside EU/EEA PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005151-42 Sponsor Protocol Number: P05101 Start Date*: 2008-08-28
    Sponsor Name:Schering Plough Research Institute, A Division of Schering Corporation
    Full Title: A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    9.1 10019744 Hepatitis C PT
    9.1 10021881 Infections and infestations SOC
    9.1 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Prematurely Ended) ES (Completed) IT (Completed) BE (Completed) DE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004864-38 Sponsor Protocol Number: P05411 Start Date*: 2009-10-02
    Sponsor Name:Schering Plough Research Institute, A Division of Schering Corporation
    Full Title: A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected with HIV and Hepatitis C
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    13.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    13.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    13.1 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) BE (Completed) FR (Completed) PT (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000073-24 Sponsor Protocol Number: CTRIAL-IE-19-33 Start Date*: 2020-09-07
    Sponsor Name:Cancer Trials Ireland
    Full Title: Paricalcitol Trial: Phase II, Open label clinical trial of Paricalcitol in combination with Gemcitabine/ Nab-Paclitaxel therapy in advanced pancreatic cancer.
    Medical condition: Advanced pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    21.0 100000004864 10033607 Pancreatic cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012782-63 Sponsor Protocol Number: P06086 Start Date*: 2010-01-08
    Sponsor Name:Schering-Plough Research Institution, A Division of Schering Corporation
    Full Title: Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Versus Ribavirin Dose Reduction for the Management of Anemia
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    12.0 10008912 Chronic hepatitis C LLT
    9.1 10019744 PT
    9.1 10021881 SOC
    9.1 10019805 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004760-39 Sponsor Protocol Number: P05685 Start Date*: 2009-04-03
    Sponsor Name:Schering Plough Research Institute, A Division of Schering Corporation
    Full Title: A phase 3 safety and efficacy study of boceprevir in combination with peginterferon alfa-2a and ribavirin in subjects with chronic hepatitis C genotype 1 who failed prior treatment with peginterfer...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    9.1 10019744 Hepatitis C PT
    9.1 10021881 Infections and infestations SOC
    9.1 10019805 Hepatobiliary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-000068-86 Sponsor Protocol Number: AROAAT2002 Start Date*: 2019-07-01
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
    Medical condition: alpha-1 antitrypsin deficiency (AATD)-associated liver disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004850 10001806 Alpha-1 anti-trypsin deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 19:54:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA